Full Press Release Details
Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
Multiple presentations
will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl)
in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma
Lausanne, Switzerland,
November 3, 2022 - ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs),
including ZYNLONTA (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th
American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, Louisiana from December 10-13, 2022.
Details of ADC Therapeutics'
Real-World Effectiveness
and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large
B-Cell Lymphoma in US
Session: 905. Outcomes
Research-Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation
Time: Monday, December 12, 2022, 4:30-6:00 p.m. CST
Location: Ernest N. Morial Convention
Presenter: Dai Chihara,
MD, The University of Texas MD Anderson Cancer Center
Details of an independently
developed oral presentation:
Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia:
Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials
Time: Saturday, December 10, 2022, 2:00-3:30 p.m. CST
N. Morial Convention Center, 265-268
Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Details of ADC Therapeutics'
poster presentations:
by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems
Pharmacology Modeling
Session: 627. Aggressive
Lymphomas: Clinical and Epidemiological: Poster III
Date and Time: Monday,
December 12, 2022, 6:00-8:00 p.m. CST
F. Caimi, MD, Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
A Phase 2, Open-Label
Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large
B-Cell Lymphoma (DLBCL) (LOTIS-9)
Session: 626. Aggressive
Lymphomas: Prospective Therapeutic Trials: Poster II
Date and Time: Sunday,
December 11, 2022, 6:00-8:00 p.m. CST
Westin, MD, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide
Session: 905. Outcomes
Research-Lymphoid Malignancies: Poster II
Date and Time: Sunday,
December 11, 2022, 6:00-8:00 p.m. CST
Hamadani, MD, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing
Session: 621. Lymphomas:
Translational-Molecular and Genetic: Poster I
Date and Time: Saturday,
December 10, 2022, 5:30-7:30 p.m. CST
Presenter: Francesco
Vallania, PhD, Freenome, San Francisco, CA
Exploratory Analysis
of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients
with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Session: 624. Hodgkin
Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I
Date and Time: Saturday,
December 10, 2022, 5:30-7:30 p.m. CST
F. Herrera, MD, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA
CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical
Session: 622. Lymphomas:
Translational-Non-Genetic: Poster III
Date and Time: Monday,
December 12, 2022, 6:00-8:00 p.m. CST
F. Herrera, MD, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA
Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
Session: 701. Experimental
Transplantation: Basic and Translational: Poster III
Date and Time: Monday,
December 12, 2022, 6:00-8:00 p.m. CST
Yeung, PhD, UCL Great Ormond Street Institute of Child Health and UCL Cancer Institute, London, United Kingdom
available in the poster exhibit hall (Hall D) of the Ernest N. Morial Convention Center on December 10 from 9:00 a.m.-7:30 p.m. CST and
December 11 & 12 from 9:00 a.m.-8:00 p.m. CST. Presenters planning to attend in person are expected to present during the final two
hours of the noted viewing time. Presentations will also be available on a virtual platform. Presenters are subject to change.
available through the ASH online meeting program and will be published in the November supplemental issue of Blood.
(loncastuximab tesirine-lpyl)
a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes
release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible
to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory
(r/r) large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, DLBCL arising from
low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three
prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory
to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior
to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and
continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
Camidanlumab tesirine
(Cami) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax -TAC, licensed from Genmab
A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized
into the cell where enzymes release the PBD-based payload, killing the cell. This applies to CD25-expressing tumor cells and also to
CD25-expressing Tregs. The intra-tumoral release of its PBD payload may also cause bystander killing of neighboring tumor cells, and
PBDs have also been shown to induce immunogenic cell death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.
Cami is being evaluated
in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy
and in combination with pembrolizumab in solid tumors.